Prostate cancer is the second most prevalent malignancy in males and the fifth leading cause of death worldwide.1 In 2021, there were approximately 248 530 cases of prostate cancer, representing more than 26% of new cancer diagnoses.2 Aside from digital rectal examination (DRE), diagnostic imaging methods, and prostate-specific antigen (PSA) testing, histopathology is regarded as the most dependable method for diagnosing prostate cancer. This evidence concerns the gene KLK3 and prostate cancer.